Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.49 |
| ▸ | DRD3 | P35462 | 6/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL979016 | 1.00 | DRD2 (0.49) | DRD2DRD3HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL979028 | 0.99 | DRD2 (0.48) | DRD2DRD3HTR1AHTR2A | |
| SCHEMBL976290 | 0.91 | DRD2 (0.51) | DRD2DRD3HTR1AHTR2A | |
| SCHEMBL976288 | 0.91 | DRD2 (0.51) | DRD2DRD3HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL976238 | 0.89 | DRD2 (0.50) | DRD2DRD3HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL976237 | 0.89 | DRD2 (0.50) | DRD2DRD3HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL15741450 | 0.88 | DRD2 (0.49) | DRD2DRD3HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL15741451 | 0.88 | DRD2 (0.49) | DRD2DRD3HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL4319207 | 0.83 | DRD2 (0.47) | DRD2DRD3HTR1AHTR2A | |
| SCHEMBL976936 | 0.83 | DRD2 (0.53) | DRD2DRD3HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802672-B2 | Pyrimidinyl-piperazines useful as D3/D2 receptor ligands | RICHTER GEDEON NYRT. (HU) | 2014-08-12 | — | — | US | disclosed |
| EP-2132185-B1 | PYRIMIDINYL-PIPERAZINES USEFUL AS DOPAMINE D3/D2 RECEPTOR LIGANDS | RICHTER GEDEON NYRT (HU) | 2011-08-03 | — | — | EP | disclosed |
| US-20110112093-A1 | PYRIMIDINYL-PIPERAZINES USEFUL AS D3/D2 RECEPTOR LIGANDS | RICHTER GEDEON NYRT. | 2011-05-12 | — | — | US | disclosed |
| US-7875610-B2 | trans-N-(4-{2-[4-(5,6-dichloro-2-methylamino-pyrimidin-4-yl)-piperazin-1-yl]-ethyl]-cyclohexyl}-acetamide; for treating Parkinson's disease; reacting trans-(4-{4-[2-(4-amino-cyclohexyl)-ethyl]-piperazin-1-yl}-5,6-dichloro-pyrimidin-2-yl)-methyl-amine trihydrochloride with acetyl chloride | RICHTER GEDEON NYRT. (HU) | 2011-01-25 | — | — | US | disclosed |
| EP-2132185-A2 | PYRIMIDINYL-PIPERAZINES USEFUL AS DOPAMINE D3/D2 RECEPTOR LIGANDS | Richter Gedeon NYRT (HU) | 2009-12-16 | — | — | EP | disclosed |
| US-20090143398-A1 | PYRIMIDINYL-PIPERAZINES USEFUL AS D3/D2 RECEPTOR LIGANDS | RICHTER GEDEON NYRT. (HU) | 2009-06-04 | — | — | US | disclosed |
| WO-2008125891-A2 | PYRIMIDINYL-PIPERAZINES USEFUL AS DOPAMINE D3 /D2 RECEPTOR LIGANDS | RICHTER GEDEON NYRT (HU) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112093-A1 | PYRIMIDINYL-PIPERAZINES USEFUL AS D3/D2 RECEPTOR LIGANDS | DRD2, DRD3, AVPR2 | DRD2 1/4885DRD3 2/4885HTR1A 107/4885 |
| US-20090143398-A1 | PYRIMIDINYL-PIPERAZINES USEFUL AS D3/D2 RECEPTOR LIGANDS | DRD2, DRD3, AVPR2 | DRD2 1/4885DRD3 2/4885HTR1A 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.